Holen Sie sich die Stockscreener-App
194.99
0.02%
0.04
Handel nachbörslich:
194.99
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$194.95
Offen:
$196.72
24-Stunden-Volumen:
1.57M
Relative Volume:
0.30
Marktkapitalisierung:
$302.39B
Einnahmen:
$58.80B
Nettoeinkommen (Verlust:
$10.24B
KGV:
59.47
EPS:
3.2788
Netto-Cashflow:
$8.98B
1W Leistung:
-3.36%
1M Leistung:
+0.82%
6M Leistung:
+141.29%
1J Leistung:
+156.60%
1-Tages-Spanne:
$194.81
$198.09
1-Wochen-Bereich:
$189.35
$203.29
52-Wochen-Spanne:
$61.24
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
194.99 | 302.33B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
LLY
Lilly Eli Co
|
1,001.35 | 900.48B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
243.71 | 584.62B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
227.01 | 402.17B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
NVS
Novartis Ag Adr
|
161.59 | 310.63B | 54.72B | 14.02B | 15.32B | 7.1855 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-27 | Eingeleitet | Citigroup | Buy |
| 2025-10-27 | Fortgesetzt | Jefferies | Buy |
| 2025-10-16 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2025-02-13 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-20 | Hochstufung | UBS | Sell → Neutral |
| 2024-11-06 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-16 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Sell |
| 2024-01-03 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-25 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-12 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-05 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-09-15 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Hochstufung | Argus | Hold → Buy |
| 2022-06-14 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-11 | Hochstufung | DZ Bank | Sell → Hold |
| 2021-12-07 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-12 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-12 | Herabstufung | Argus | Buy → Hold |
| 2021-03-16 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Hochstufung | UBS | Neutral → Buy |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-12-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Hochstufung | UBS | Sell → Neutral |
| 2020-11-11 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2019-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-10-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-02 | Herabstufung | UBS | Neutral → Sell |
| 2019-02-05 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2019-01-25 | Hochstufung | Shore Capital | Hold → Buy |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-08-16 | Herabstufung | Jefferies | Buy → Hold |
| 2018-03-19 | Hochstufung | Jefferies | Hold → Buy |
| 2018-02-06 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-05 | Bestätigt | Bernstein | Outperform |
| 2018-01-18 | Bestätigt | Leerink Partners | Mkt Perform |
| 2017-12-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Hochstufung | Bernstein | Mkt Perform → Outperform |
Alle ansehen
Astrazeneca Plc Aktie (AZN) Neueste Nachrichten
AstraZeneca and Daiichi Sankyo Enter Global Collaboration to Jointly Develop and Commercialize Enhertu - marketscreener.com
AstraZeneca (AZN) Achieves Priority Review for Enhertu in Breast Cancer Treatment - GuruFocus
AstraZeneca, Daiichi Sankyo Wins Priority Review for Enhertu for Breast Cancer - marketscreener.com
AstraZeneca (AZN) and Other Drugmakers Watch as Key FDA Official Resigns - GuruFocus
AstraZeneca’s AZD5004 Formulation Trial: Early Data Point for Long-Term Pipeline Value - TipRanks
AstraZeneca executives receive vested shares under deferred bonus plan - Investing.com India
AstraZeneca CEO Pascal Soriot receives vested shares under performance plan - Investing.com UK
AstraZeneca awards share grants to CEO and CFO under company incentive plans - Investing.com Nigeria
AstraZeneca (AZN) CEO awarded 101,495 shares on AZPSP vesting - Stock Titan
AstraZeneca (NYSE: AZN) awards deferred bonus shares to leaders - Stock Titan
Jefferies raises AstraZeneca target to 18,000p as analysts flip view on delayed cancer trial - Proactive Investors
Longfellow Investment Management Co. LLC Makes New Investment in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC $AZN Stock Holdings Raised by Orion Porfolio Solutions LLC - MarketBeat
AstraZeneca Executives Receive Vested Deferred Share Awards - TipRanks
AstraZeneca Grants Long-Term Share Awards to CEO and CFO - TipRanks
The Zacks Analyst Blog Highlights Exxon Mobil, Palantir, AstraZeneca, Gencor Industries and Hour Loop - Nasdaq
243,177 Shares in AstraZeneca PLC $AZN Purchased by Foresight Global Investors Inc. - MarketBeat
Top Analyst Reports for Exxon Mobil, Palantir & AstraZeneca - Yahoo Finance
GLP-1 Receptor Agonist (Trulicity, Wegovy, Ozempic, Mounjaro) Market Trends Analysis Report 2026 - GlobeNewswire Inc.
Xencor falls on royalty row with AstraZeneca (XNCR:NASDAQ) - Seeking Alpha
HAP Trading LLC Sells 7,267 Shares of AstraZeneca PLC $AZN - MarketBeat
Mengis Capital Management Inc. Boosts Stock Position in AstraZeneca PLC $AZN - MarketBeat
Dimensional Fund Advisors LP Raises Stake in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC $AZN Position Lessened by Teachers Retirement System of The State of Kentucky - MarketBeat
AstraZeneca (AZN) Strengthens Clinical Portfolio and Expands Inv - GuruFocus
GLP-1 Receptor Agonist Business Analysis Report 2026: Market to Reach $137.4 Billion by 2030 - GlobeNewswire Inc.
CI Investments Inc. Has $18.33 Million Holdings in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca Advances Food-Effect Trial for New Cardio-Renal Combo Tablet - TipRanks
AstraZeneca (AZN) adds three fixed-rate US dollar note issues out to 2036 - Stock Titan
AstraZeneca PLC (AZN) Investor Outlook: Evaluating the Healthcare Giant Amidst a -21.01% Potential Downside - DirectorsTalk Interviews
Morqan Stanley Raises Astrazeneca Price Target to $219 From $109, Overweight Rating Kept - marketscreener.com
AstraZeneca reports total voting rights of over 1.55 billion shares - Investing.com
AstraZeneca (LSE/STO/NYSE: AZN) details 1.55B voting rights - Stock Titan
Fisher Asset Management LLC Acquires 466,745 Shares of AstraZeneca PLC $AZN - MarketBeat
ASTRAZENECA : JP Morgan maintains a Buy rating - marketscreener.com
Rafferty Asset Management LLC Sells 7,892 Shares of AstraZeneca PLC $AZN - MarketBeat
Becker Capital Management Inc. Decreases Position in AstraZeneca PLC $AZN - MarketBeat
Antibiotics Market - GlobeNewswire Inc.
AstraZeneca Says Breast Cancer Treatment Granted US FDA Priority Review - marketscreener.com
American Century Companies Inc. Has $167.79 Million Stock Holdings in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC (AZN.L) Stock Report: Analyzing a Healthcare Powerhouse with a $241 Billion Market Cap - DirectorsTalk Interviews
AstraZeneca PLC (NASDAQ:AZN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
AstraZeneca PLC $AZN Shares Bought by US Bancorp DE - MarketBeat
Harvest Portfolios Group Inc. Sells 20,219 Shares of AstraZeneca PLC $AZN - MarketBeat
AlphaCore Capital LLC Increases Stock Position in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC $AZN Shares Acquired by TD Asset Management Inc - MarketBeat
Erste Asset Management GmbH Sells 29,313 Shares of AstraZeneca PLC $AZN - MarketBeat
AstraZeneca’s Strategic Leap: Pharmaceutical Giant Completes Historic Move to the New York Stock Exchange - FinancialContent
Thornburg Investment Management Inc. Sells 24,703 Shares of AstraZeneca PLC $AZN - MarketBeat
AstraZeneca has 'sector leading replacement power' to cope with 2030 patent cliff - Yahoo Finance UK
AstraZeneca (AZN) prices $2bn in new fixed-rate global bond tranches - Stock Titan
Finanzdaten der Astrazeneca Plc-Aktie (AZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):